<DOC>
	<DOC>NCT02066545</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris</brief_summary>
	<brief_title>Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Male or nonpregnant female subjects with facial acne vulgaris, 12 years of age or older. Subjects with â‰¥20 inflammatory facial lesions (papules, pustules) inclusive of the nose, with a maximum of 9 inflammatory pustules. An Investigator's Global Assessment (IGA) of Moderate (3) or Severe (4) Subjects with acne conglobate, acne fulminans, and secondary acne (chloracne, druginduced acne, polycystic ovarian syndrome, etc.) Subjects with greater that 75 facial noninflammatory lesions (open and/or closed comedones; excluding the nose) Subjects with more than 2 facial nodulocystic lesions</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>